Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
- PMID: 26341922
- DOI: 10.1158/1078-0432.CCR-14-2796
Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Abstract
Purpose: Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors. The mechanisms by which CCND2 is upregulated in a set of multiple myeloma are not completely deciphered. We investigated the role of post-transcriptional regulation through the interaction between miRNAs and their binding sites at 3'UTR in CCND2 overexpression in multiple myeloma.
Experimental design: Eleven myeloma cell lines and 45 primary myeloma samples were included in the study. Interactions between miRNAs deregulated in multiple myeloma and mRNA targets were analyzed by 3'UTR-luciferase plasmid assay. The presence of CCND2 mRNA isoforms different in length was explored using qRT-PCR, Northern blot, mRNA FISH, and 3' rapid amplification of cDNA ends (RACE)-PCR.
Results: We detected the presence of short CCND2 mRNA, both in the multiple myeloma cell lines and primary cells. The results obtained by 3'RACE experiments revealed that changes in CCND2 3'UTR length are explained by alternative polyadenylation. The luciferase assays using plasmids harboring the truncated CCND2 mRNA strongly confirmed the loss of miRNA sites in the shorter CCND2 mRNA isoform. Those multiple myelomas with greater abundance of the shorter 3'UTR isoform were associated with significant higher level of total CCND2 mRNA expression. Furthermore, functional analysis showed significant CCND2 mRNA shortening after CCND1 silencing and an increased relative expression of longer isoform after CCND1 and CCND3 overexpression, suggesting that cyclin D1 and D3 could regulate CCND2 levels through modifications in polyadenylation-cleavage reaction.
Conclusions: Overall, these results highlight the impact of CCND2 3'UTR shortening on miRNA-dependent regulation of CCND2 in multiple myeloma.
©2015 American Association for Cancer Research.
Similar articles
-
Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.Leuk Res. 2008 Jan;32(1):79-88. doi: 10.1016/j.leukres.2007.05.021. Epub 2007 Jul 16. Leuk Res. 2008. PMID: 17629555
-
LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer.Cell Physiol Biochem. 2018;49(4):1289-1303. doi: 10.1159/000493408. Epub 2018 Sep 11. Cell Physiol Biochem. 2018. PMID: 30205383
-
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.Blood. 2019 Feb 28;133(9):940-951. doi: 10.1182/blood-2018-07-862151. Epub 2018 Dec 11. Blood. 2019. PMID: 30538135 Free PMC article.
-
Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta-analysis.Cancer Med. 2019 Jun;8(6):2717-2729. doi: 10.1002/cam4.2152. Epub 2019 Apr 5. Cancer Med. 2019. PMID: 30950241 Free PMC article.
-
The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells.RNA Biol. 2012 May;9(5):563-76. doi: 10.4161/rna.20231. Epub 2012 May 1. RNA Biol. 2012. PMID: 22614827 Review.
Cited by
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.Haematologica. 2024 Mar 1;109(3):877-887. doi: 10.3324/haematol.2023.283445. Haematologica. 2024. PMID: 37646661 Free PMC article.
-
Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):397-405. doi: 10.1016/j.clml.2019.03.017. Epub 2019 Mar 25. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31036508 Free PMC article. Review.
-
Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.Blood Adv. 2018 Nov 13;2(21):2879-2889. doi: 10.1182/bloodadvances.2018019398. Blood Adv. 2018. PMID: 30381403 Free PMC article.
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545347 Free PMC article.
-
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z. Signal Transduct Target Ther. 2025. PMID: 40675967 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials